NODE N.06 / FAQ
Fifteen questions, answered against the published record.
Each answer cites the same primary literature indexed on /research and /references. No speculation, no protocols.
What is CJC-1295 and how is it structurally different from native GHRH?
CJC-1295 is a 30-residue peptide. Its first 29 residues are a tetra-substituted analog of human GHRH(1-29) with four engineered swaps: D-Ala at position 2 (blocks DPP-4 cleavage), Gln at 8 (prevents asparagine rearrangement), Ala at 15 (raises receptor affinity), and Leu at 27 (removes the oxidation-prone methionine) [1]. The thirtieth residue is C-terminal Lys30, which carries a maleimidopropionic-acid group — the Drug Affinity Complex (DAC) handle. Native GHRH is a 44-amino-acid hypothalamic peptide; sermorelin is the unmodified hGRF(1-29) fragment with a plasma half-life of roughly 11 to 12 minutes. CJC-1295 differs from sermorelin in four backbone residues and one terminal handle, and the half-life shift is roughly ten thousand-fold [1] [16].
How does the DAC handle actually extend the half-life?
The maleimide group is a cyclic imide highly selective for free thiols. Once CJC-1295 is injected subcutaneously, the maleimide reacts via Michael addition with the free cysteine thiol on Cys34 of circulating serum albumin, forming a stable thioether bond [1]. The peptide does not circulate as a free peptide — it circulates as a covalent peptide-albumin conjugate. Albumin has a circulating half-life of approximately 19 days, and the body continuously regenerates the albumin pool, so the tethered peptide is continuously presented to the pituitary GHRH receptor [1] [2]. The 5.8 to 8.1 day plasma half-life estimated in healthy humans is the consequence [2].
What did the Teichman 2006 trial actually find?
The Teichman 2006 trial in the Journal of Clinical Endocrinology and Metabolism is the pivotal Phase 1 human pharmacokinetic study of CJC-1295 [2]. Single subcutaneous doses of 30 to 250 microgram per kilogram in healthy adults produced two- to tenfold elevations in mean plasma GH sustained for six or more days, and 1.5- to threefold elevations in IGF-1 sustained for nine to eleven days. Estimated plasma half-life: 5.8 to 8.1 days. Multiple-dose 60 microgram per kilogram weekly for 28 to 49 days produced cumulative IGF-1 elevation lasting roughly 28 days. The most common adverse events were injection-site reactions; no serious drug-related adverse events were reported at doses up to 60 microgram per kilogram [2] [14].
Why was the Phase 2 HIV-lipodystrophy trial halted?
NCT00267527 enrolled 192 HIV-positive patients with visceral lipodystrophy and randomized them to once-weekly subcutaneous CJC-1295 (escalating 60 to 120 or 60 to 240 microgram per kilogram) or placebo for twelve weeks [11]. The trial was halted after a participant cardiac death two hours after the eleventh weekly dose. The attending physician adjudicated the event as related to pre-existing coronary artery disease and unrelated to study drug. The body-composition primary endpoints were never published in peer-reviewed literature [11]. The question of whether this is a safety signal cannot be answered from the public record alone — adjudication does not equal full peer-reviewed analysis, and the trial population (HIV-positive adults with metabolic complications) had higher baseline cardiovascular risk than the Phase 1 healthy-volunteer cohort. No replication trial has been registered.
What is the difference between 'CJC-1295 with DAC' and 'CJC-1295 no DAC'?
CJC-1295 with DAC is the full 30-residue peptide as originally characterized — the tetra-substituted hGRF(1-29) backbone plus the Lys30 maleimidopropionic-acid handle that covalently binds albumin. Plasma half-life in healthy humans: 5.8 to 8.1 days [2]. 'CJC-1295 no DAC' is a gray-market name for the 29-residue tetra-substituted backbone without the maleimide handle. Without the handle, the peptide circulates freely and is cleared in roughly 30 minutes — a half-life about ten thousand-fold shorter than the DAC-bearing variant [16]. The two compounds share four backbone substitutions and the GHRH-R binding pocket; they differ in carrier chemistry, half-life, dosing kinetics, and pharmacodynamic profile. Marketing materials frequently conflate them; the published literature does not [10] [16].
How is CJC-1295 detected in anti-doping testing if albumin conjugation hides it?
Standard top-down mass-spectrometric workflows fail on CJC-1295 because the molecular weight of the circulating species varies — the peptide attaches not only to albumin Cys34 but also to a heterogeneous mixture of plasma thiols [12]. The analytical literature works around this in two ways. Bottom-up tryptic-digest workflows release a signature peptide from the albumin carrier and identify the signature peptide by LC-MS/MS — Timms 2019 reaches approximately 180 pg/mL in equine plasma [7], Knoop 2016 reaches below 50 pg/mL in human plasma [8]. Antibody-based capture uses paired monoclonal antibodies against CJC-1295 to enrich the conjugate before detection — Timms 2019 reports an I-PCR LOD of 0.8 pg/mL with a practical screening threshold of 50 pg/mL [6]. Knoop 2022 demonstrates an antibody-free ultrafiltration-based nanoLC-HRMS/MS method for urine at 5 to 25 pg/mL [9]. The compound is detectable; the analytical chain is just unusual.
Has CJC-1295 ever been approved by any regulatory authority?
No. CJC-1295 has never received marketing authorization from FDA, EMA, MHRA, TGA, PMDA, or any other regulator for any indication. The compound progressed through Phase 1 and entered Phase 2 in HIV-lipodystrophy; the Phase 2 program was terminated before completion and no formal regulatory submission was filed [11]. The compound is a research chemical in regulatory terms. The World Anti-Doping Agency lists CJC-1295 by name under Section S2 of the Prohibited List (Peptide Hormones, Growth Factors, Related Substances and Mimetics), subsection 2.3 (GHRH and its analogs and mimetics), prohibited at all times for athletes under WADA jurisdiction.
What are the documented adverse effects in research subjects?
In the Phase 1 program, the most frequently reported adverse events were injection-site reactions: transient pain, swelling, induration, occasional local urticaria — generally mild and short-lived [2] [14]. Pharmacological doses produced dose-dependent water retention and joint stiffness consistent with sustained GH/IGF-1 elevation. No serious drug-related adverse events were reported at doses up to 60 microgram per kilogram [2] [14]. In the Phase 2 program, one participant cardiac death occurred two hours after the eleventh weekly dose; the event was adjudicated as drug-unrelated and attributed to pre-existing coronary artery disease [11]. Adverse-event reporting in non-trial contexts (gray-market use) is not characterized in the peer-reviewed literature.
Is the IGF-1 elevation a cancer-risk concern?
Epidemiologic data — independent of CJC-1295 — consistently associate chronically elevated IGF-1 with modestly higher risk of certain cancers including prostate, breast, and colorectal [17]. The Renehan 2004 Lancet meta-analysis quantified the association across population-level cohorts. The 1.5- to threefold IGF-1 elevations observed for nine to twenty-eight days after CJC-1295 dosing in healthy adults have not been studied against cancer-incidence endpoints, and no causal link between CJC-1295 specifically and human carcinogenesis has been demonstrated [17]. The mechanistic concern is reasonable; the empirical answer for this compound is unresolved.
What is the relationship between CJC-1295 and ipamorelin?
CJC-1295 binds the GHRH receptor (a class B GPCR). Ipamorelin binds the growth-hormone-secretagogue receptor 1a (GHS-R1a, the ghrelin receptor — a class A GPCR). The two receptors share the same downstream output (somatotroph GH exocytosis) but engage different upstream signaling. Cunha and Mayo (2002) demonstrated that matched-dose co-administration of a GHRH analog and a GHS produces six- to tenfold greater GH release than either single agent — supraadditive convergence on intracellular calcium-dependent exocytosis [13]. This is the mechanistic rationale for the widely studied CJC-1295 plus ipamorelin pairing in research models. There is no published Phase 2 or Phase 3 trial of the combination in humans.
What is 'somatopause' and where does CJC-1295 sit in that conversation?
Aging humans show a progressive decline in GH pulse amplitude and circulating IGF-1 — a phenomenon described as 'somatopause' that has been associated with sarcopenia, increased visceral adiposity, and decreased bone density [18]. Daily sermorelin at 0.5 milligram subcutaneously for six months in older adults raised IGF-1 by approximately 35 percent with measured increases in lean body mass and decreases in abdominal fat [18]. CJC-1295 has been proposed in research literature as a less-frequent-dosing equivalent to daily sermorelin, but no comparable age-related decline trial has been conducted at scale for CJC-1295 [18]. The somatopause framing is currently a sermorelin-evidenced framing with a CJC-1295 hypothesis attached.
Why does this site exist if CJC-1295 is not approved and not sold here?
Because the published record on CJC-1295 is small, finite, and frequently misrepresented in secondary literature. The same six citations appear over and over in lifestyle medicine and forum content, often misquoted, often conflated between 'CJC-1295 with DAC' and 'CJC-1295 no DAC' variants, and often paired with dosing protocols that no trial ever administered. An editorial summary that reads the actual papers, cites them correctly, and organizes the network of findings as a navigable graph is useful as a reference point — independent of whether any reader intends any non-research use. This site is an independent editorial research digest.
Does the 'order' in the domain name mean this site accepts orders?
No. The 'order' modifier is editorial framing — the position the publisher occupies relative to the literature, not a claim about services offered. The about page expands on the entity question. The footer disclaimer on every page frames the editorial contract: an independent research digest, not a clinic, not a vendor.
What does 'WADA S2 prohibited' mean in practice?
The World Anti-Doping Agency Prohibited List divides banned substances into categories. Section S2 covers peptide hormones, growth factors, related substances, and mimetics. Subsection 2.3 specifically covers growth-hormone-releasing hormone and its analogs and mimetics, with CJC-1295 listed by name. 'Prohibited at all times' means the substance is banned both in-competition (during the day of competition and the day before, in most sports) and out-of-competition (every other day of the calendar year) for athletes registered in a WADA-tested testing pool. Detection in plasma or urine samples by any of the validated analytical methods described in the research literature is grounds for sanction [6] [7] [8] [9]. Different sports and different countries operate different jurisdictions on top of the WADA framework; the WADA listing is the floor, not the ceiling.
Where do the citations on this site come from?
Every quantitative claim cites a primary source — the original Endocrinology, Journal of Clinical Endocrinology and Metabolism, Lancet, Drug Testing and Analysis, Analytical and Bioanalytical Chemistry, Journal of Pharmaceutical and Biomedical Analysis, or ClinicalTrials.gov entry. The /references page lists all sources with DOIs and PubMed/PMC URLs. The /research page tags each finding with a node coordinate (N.01 through N.18) and a status-pulse marker for category (mechanism, clinical, forensic, regulatory). No claim on this site originates from a forum post, an anonymous blog, or a vendor marketing page.